An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia

@inproceedings{Pandina2012AnOM,
  title={An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia},
  author={Gahan Pandina and Stuart F Kushner and Keith Karcher and Magali Haas},
  booktitle={Child and adolescent psychiatry and mental health},
  year={2012}
}
BACKGROUND Data on the long-term efficacy, safety, and tolerability of risperidone in adolescents with schizophrenia are limited. The objective of this study was to evaluate the efficacy and safety of maintenance risperidone treatment in adolescents with schizophrenia. METHODS This open-label study of adolescents aged 13 to 17 years with schizophrenia was a single extension study of two short-term double-blind risperidone studies and also enrolled subjects directly in open-label risperidone… CONTINUE READING
4 Citations
42 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 42 references

Clinical global impressions (CGI). In Guy W (ed): ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 1976:218–222

  • W Guy
  • 1976
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…